Breaking News Instant updates and real-time market news.

HIMX

Himax

$8.64

0.04 (0.47%)

, TZA

Small Cap Bear 3x

$26.98

-0.52 (-1.89%)

08:45
10/06/16
10/06
08:45
10/06/16
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Himax Technologies (HIMX) 9.54% +0.85, Direxion Daily Small Cap Bear 3X Shares (TZA) 4.19% +0.64, ProShares Short VIX Short Term Futures (SVXY) 5.01% +0.46, Restoration Hardware (RH) 5.85% +0.36, 3D (DDD) 2.64% +0.33, ProShares Ultra DJ UBS Crude Oil (UCO) 1.59% +0.30, ProShares Ultra VIX Short Term Futures (UVXY) 5.63% +0.28, Genworth Financial (GNW) 1.79% +0.28, Sprint (S) 0.90% +0.27, and Teva (TEVA) 0.62% +0.26.

HIMX

Himax

$8.64

0.04 (0.47%)

TZA

Small Cap Bear 3x

$26.98

-0.52 (-1.89%)

RH

Restoration Hardware

$34.68

0.71 (2.09%)

DDD

3D Systems

$18.32

0.45 (2.52%)

UCO

Universal Compression

$11.15

0.49 (4.60%)

GNW

Genworth

$5.14

0.07 (1.38%)

S

Sprint

$6.66

-0.04 (-0.60%)

TEVA

Teva

$45.19

-0.07 (-0.15%)

  • 25

    Oct

  • 01

    Nov

  • 06

    Nov

  • 15

    Nov

HIMX Himax
$8.64

0.04 (0.47%)

09/29/16
FBCO
09/29/16
NO CHANGE
FBCO
Outperform
Himax long-term story intact, says Credit Suisse
Credit Suisse analyst Jerry Su lowered Himax's LCOS/WLO shipment assumptions for Q4-1H 2017 on slower new platform adoption following supply chain checks. Su said the 2018 AR device ramp is on track and believes Himax's long-term story on consumer AR glass and 3D sensing for smartphone remains intact, since the capacity ramp up remains on schedule. The analyst said the potential launch of consumer AR glass and 3D sensing for smartphone should boost Himax's earnings in 2018 and reiterates his Outperform rating and $14 price target.
09/28/16
ROTH
09/28/16
INITIATION
Target $10
ROTH
Buy
Himax initiated with a Buy at Roth Capital
Roth Capital analyst Suji Desilva initiated Himax with a Buy and a $10 price target. Desilva believes newer HIMX products can participate in growth of IoT device categories such as augmented reality and virtual reality head-mounted devices.
09/26/16
NOMU
09/26/16
DOWNGRADE
NOMU
Neutral
Himax downgraded to Neutral from Buy at Nomura
09/02/16
NOMU
09/02/16
NO CHANGE
Target $12
NOMU
Buy
Himax price target raised to $12 on better pricing at Nomura
Nomura analyst Donnie Teng noted that Himax has been able to raise its prices for its liquid crystal on silicon, or LCOS, and wafer level optics, or WLO, for a major augmented reality device recently, which he believes could help the company reach the higher end of its Q3 sales guidance. Teng raised his price target on Himax shares to $12 from $9.70, adding that the company plans to try to provide more cost effective LCOS and WLO products for a possible consumer AR device in 2018, which lead to higher demand. Nomura keeps a Buy rating on the stock.
TZA Small Cap Bear 3x
$26.98

-0.52 (-1.89%)

RH Restoration Hardware
$34.68

0.71 (2.09%)

09/09/16
COWN
09/09/16
NO CHANGE
Target $33
COWN
Market Perform
Restoration Hardware strength not justified, says Cowen
Cowen analyst Oliver Chen believes the after-market strength in Restoration Hardware shares following the company's Q2 earnings beat is not justified. The analyst said the beat was driven by the low-quality pull forward of Q3 demand, since comps were running negative and deteriorating in the second half. He believes there is still too much uncertainty in sales inflection, execution issues, and negative free cash flow for investors to get involved. Chen maintained his Market Perform rating and lowered his price target to $33 form $35 on Restoration Hardware shares.
09/09/16
DBAB
09/09/16
NO CHANGE
Target $40
DBAB
Hold
Restoration Hardware Q2 upside driven by pull forward, says Deutsche Bank
Deutsche Bank analyst Adam Sindler attributes Restoration Hardware's upside in Q2 to pull forward from Q3. The pull forward of sales into Q2 from Q3 is primarily related to outdoor furniture, Sindler tells investors in a research note. He points out the company reiterated its annual guidance despite the upside in Q2. Nonetheless, the analyst believes Restoration's trends are stabilizing and he upped his price target for the shares to $40 from $28. Sindler reiterates a Hold rating on the name. The stock is up 11% to $39.00 in pre-market trading.
09/29/16
OPCO
09/29/16
NO CHANGE
OPCO
Restoration Hardware rally a selling opportunity, says Oppenheimer
09/09/16
GSCO
09/09/16
NO CHANGE
Target $45
GSCO
Conviction Buy
Restoration Hardware price target raised to $45 from $40 at Goldman
Goldman analyst Matthew Fassler raised Restoration Hardware's price target to $45 from $40 and increased its FY17 earnings estimate to $2.48 from $2.42 and FY18 to $2.88 from $2.78 following the Q2 beat and maintained his Conviction Buy rating.
DDD 3D Systems
$18.32

0.45 (2.52%)

09/15/16
KEYB
09/15/16
NO CHANGE
KEYB
3D printer, robot companies can benefit from manufacturing trend, says KeyBanc
After attending a manufacturing technology show, KeyBanc expects "short-cycle" OEMs to "remain focused on cost savings and efficiency improvement." 3D printing and "collaborative robot" systems can help meet this goal, according to the firm. The trend is positive for 3D Systems (DDD), Stratasys (SSYS), Materialise (MTLS), and Teradyne (TER), according to the firm. It keeps an Overweight rating on Materialise and Sector Weight ratings on the remaining companies named.
10/03/16
10/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. 3D Systems (DDD) coverage transferred with a Market Perform at FBR Capital. 2. Carnival (CCL) initiated with a Buy at HSBC. 3. GoDaddy (GDDY) initiated with a Buy at Summit Redstone. 4. Versum Materials (VSM) initiated with a Buy at Seaport Global. 5. ExOne (XONE) coverage transferred with an Outperform at FBR Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/16
PACS
08/04/16
NO CHANGE
PACS
3D Systems strategy 'underwhelming,' says Pacific Crest
After 3D Systems reported higher than expected EPS but lower than expected revenue, Pacific Crest analyst Weston Twigg says he's skeptical of the company's strategy of creating a closed 3D printing ecosystem, aprtly because of the company's limited R&D budget and his belief that customers will try to find best-in-class providers in each segment. However, the analyst says that 3D Systems' analyst event next month could provide a positive catalyst for the stock. He keeps a Sector Weight rating on the shares.
10/03/16
FBRC
10/03/16
INITIATION
Target $18
FBRC
Market Perform
3D Systems coverage transferred with a Market Perform at FBR Capital
FBR Capital transferred coverage on 3D Systems to analyst Christopher Van Horn who has a Market Perform rating and a $18 price target on shares.
UCO Universal Compression
$11.15

0.49 (4.60%)

GNW Genworth
$5.14

0.07 (1.38%)

09/22/16
WELS
09/22/16
INITIATION
WELS
Market Perform
Genworth coverage resumed with a Market Perform at Wells Fargo
10/05/16
BTIG
10/05/16
DOWNGRADE
BTIG
Neutral
Genworth downgraded to Neutral from Buy at BTIG
BTIG analyst Mark Palmer downgrading Genworth Financial to Neutral and removed its price target of $5 citing valuation.
11/17/15
11/17/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Antero Resources (AR) initiated with a Buy at Goldman... Applied Micro Circuits (AMCC) initiated with a Buy at Drexel Hamilton... Arc Logistics (ARCX) initiated with a Buy at DA Davidson... CNO Financial (CNO) initiated with a Buy at Goldman... Capstone Turbine (CPST) initiated with a Perform at Oppenheimer... Dominion (D) initiated with an Outperform at Scotia Howard Weil... Duke Energy (DUK) initiated with a Sector Perform at Scotia Howard Weil... EQT Corporation (EQT) initiated with a Neutral at Goldman... EverBank (EVER) initiated with a Hold at Sandler O'Neill... Exelon (EXC) initiated with a Sector Perform at Scotia Howard Weil... First Data (FDC) initiated with a Neutral at BTIG... Genworth (GNW) initiated with a Neutral at Goldman... Marinus Pharmaceuticals (MRNS) initiated with a Buy at Jefferies... New Relic (NEWR) initiated with a Buy at Needham... NextEra Energy Partners (NEP) initiated with a Sector Perform at Scotia Howard Weil... NextEra Energy (NEE) initiated with an Outperform at Scotia Howard Weil... PG&E (PCG) initiated with a Neutral at Citi... Reinsurance Group (RGA) initiated with a Sell at Goldman... The Advisory Board (ABCO) initiated with an Overweight at JPMorgan... Torchmark (TMK) initiated with a Neutral at Goldman... Ubisoft Entertainment (UBSFY) initiated with a Buy at Jefferies.
09/19/16
COMP
09/19/16
DOWNGRADE
COMP
Neutral
Genworth downgraded to Neutral from Buy at Compass Point
S Sprint
$6.66

-0.04 (-0.60%)

09/15/16
FBCO
09/15/16
NO CHANGE
Target $150
FBCO
Outperform
Credit Suisse raises Apple iPhone estimates on survey, carrier comments
Credit Suisse analyst Kulbinder Garcha said that build plans noted by the firm's tech team in Japan, the firm's proprietary iPhone survey and recent announcements from Sprint (S) and T-Mobile (TMUS) all lead him to now believe that Apple's (AAPL) iPhone 7 cycle may be stronger than anticipated. Accordingly, Garcha increased his calendar year 2016 iPhone volume estimate to 215M from 208M and took his calendar year 2017 estimate up to 221M units from 217M units. Additionally, two recent surveys conducted by the firm point to a potential beneficial mix shift, as more buyers appear to be shifting toward the Plus model compared to the mix in the iPhone 6s cycle, Garcha tells investors. The analyst reiterates an Outperform rating and $150 price target on Apple shares, which closed yesterday at $111.77.
09/13/16
WELS
09/13/16
NO CHANGE
WELS
Market Perform
Apple iPhone 7 strength consistent with view, says Wells Fargo
Wells Fargo analyst Maynard Um says the iPhone 7 pre-order strength announced by T-Mobile (TMUS) and Sprint (S) is consistent with his view that "aggressive carrier promotions" should help to drive sales of the next generation phone. Um still expects Apple's multiple expansion to be limited given the "limited visibility and some concern into the March quarter." The analyst keeps a Market Perform rating on Apple shares with a $105-$120 price target range.
09/12/16
DBAB
09/12/16
DOWNGRADE
DBAB
Hold
SoftBank downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Peter Milliken downgraded Softbank (SFTBY) to Hold saying the company's rebuilding efforts should take time. The analyst expects the stock to trade largely in line with Alibaba (BABA), Sprint (S) and the yen over the next 12 months, and he feels much of the upside has already been realized in the first two.
09/20/16
PIPR
09/20/16
NO CHANGE
PIPR
Overweight
Piper survey shows decline in iPhone upgrade interest
Piper Jaffray analyst Gene Munster says his firm's survey of 403 U.S. iPhone owners suggests that interest in an iPhone 7 upgrade declined after the announcement of the device. The data contradicts "generally positive" initial demand indicators including from carriers including T-Mobile (TMUS) and Sprint (S), Munster tells investors in a research note. The analyst questions iPhone 7 demand into Apple's (AAPL) March and June quarters but remains confident in his thinking for flattish growth for iPhone 7 versus iPhone 6. Munster reiterates an Overweight rating on Apple.
TEVA Teva
$45.19

-0.07 (-0.15%)

09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
09/29/16
OTRG
09/29/16
INITIATION
OTRG
Positive
Teva initiated with a Positive at OTR Global
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Outperform
Teva shares suffering from lack of catalysts, says Wells Fargo
Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.
10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.

TODAY'S FREE FLY STORIES

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.